{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-027370","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2021-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.393431+00:00","generated_at":"2026-06-28T12:08:43.908348+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biotricity Q2 FY2022 revenue $1.81M (+143% YoY); net loss $11M includes $5.46M one-time costs","bullets":["Revenue of $1.81 million, up 143% year-over-year; gross margin 62%.","Net loss $11.0M ($0.256/sh); adjusted net loss $5.2M ($0.128/sh) excluding $5.46M Nasdaq up-listing costs.","Ended quarter with $11.7 million cash, strongest balance sheet ever.","Announced Biokit personal medical device kit for home-use cardiac monitoring; commercial launch planned Q1 2022.","Revenue impacted by hurricanes and COVID clinic closures in southern US; expects recapture in subsequent months."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-027370","json":"https://secwatch.observer/filing/0001493152-21-027370.json","markdown":"https://secwatch.observer/filing/0001493152-21-027370.md","text":"https://secwatch.observer/filing/0001493152-21-027370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315221027370/0001493152-21-027370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315221027370/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T12:08:43.908348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}